News

The designation to SLN124 was granted by the Committee for Orphan Medicinal Products (COMP), a committee of the European Medicines Agency (EMA). COMP after reviewing an application filed

As part of the deal, Sanofi will use the BiXAb platform of Biomunex to generate and enhance bi-specific and multi-specific antibodies. Sanofi will take responsibility for the research,

Bioharmony licensed this technology from the Rockefeller University. The discoveries are from the laboratory of Vincent A. Fischetti, Ph.D., a faculty member at The Rockefeller University. Recently, the

HCC is the most common form of liver cancer and the fastest-rising cause of cancer-related death in the U.S. “This new indication for CABOMETYX is an important treatment

The pharma giant filed two new drug applications (NDAs) with the regulator covering the two forms of tafamidis – meglumine salt and free acid. The company said that

Puma Biotechnology filed a new drug submission for NERLYNX® with Health Canada in July 2018 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast

KN035 is an investigational programmed cell death ligand-1 (PD-L1) monoclonal antibody which has been exposed to more than 500 patients in multiple clinical trials in US, China and

Charles River said it is reaffirming the commitment to the future of drug discovery by advancing its integrated, innovative early-stage platform. As part of the deal, the partnership

US 10,166,194, entitled “Hydrocortisone Controlled Release Formulation”, is a patent claiming a method of treatment for adrenal dysfunction, including the diseases congenital adrenal hyperplasia (CAH) and adrenal insufficiency